The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. After a pivotal trial failure two years ago in unresected locally advanced head and neck ...

Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a perioperative regimen in certain patients with head and neck cancer ...

Oct 7 (Reuters) - Merck (MRK.N), opens new tab is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine in order to ward off ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Are you a print subscriber? Activate your account. By Tim Nudd - 2 hours 18 min ago By Babar Rahman - 4 hours 13 min ago By Tim Nudd - 7 hours 53 min ago By Brian Bonilla - 9 hours 12 min ago 9 ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

The 11th Edition of Merck Foundation Africa Asia Luminary was officially inaugurated by The President of the United Republic of Tanzania, H.E. Dr. SAMIA SULUHU HASSAN, Chairman of Merck Foundation ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options begin trading today, for the February 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...